The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Open accessAbstract
Therapeutic blocking of the PD1 pathway results in significant tumor responses, but resistance is common. We demonstrate that prolonged interferon signaling orchestrates PDL1-dependent and PDL1-independent resistance to immune checkpoint blockade (ICB) and to combinations such as radiation plus anti-CTLA4. Persistent type II interferon signaling allows tumors to acquire STAT1-related epigenomic changes and augments expression of interferon-stimulated genes and ligands for multiple T cell inhibitory receptors. Both type I and II interferons maintain this resistance program. Crippling the program genetically or pharmacologically interferes with multiple inhibitory pathways and expands distinct T cell populations with improved function despite expressing markers of severe exhaustion. Consequently, tumors resistant to multi-agent ICB are rendered responsive to ICB monotherapy. Finally, we observe that biomarkers for interferon-driven resistance associate with clinical progression after anti-PD1 therapy. Thus, the duration of tumor interferon signaling augments adaptive resistance and inhibition of the interferon response bypasses requirements for combinatorial ICB therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IFN γ and TNF α are key effector cytokines that contribute to anti-tumour immune responses 9,11,27-30 , and genes associated with IFN and TNF signaling pathways contribute to immune evasion 4,9,29 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Chronic IFN signaling can also promote an immune suppressive environment126.”
From The role of retrotransposable elements in ageing and age-associated diseases (2021) · cites this paper as [126]
In the citing paper
“The expression of PD-L1 and MHC II, which may cause exhaustion by binding to T-cell programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3), respectively, is regulated by tumor interferon (IFN) signaling.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“In solid tumors, a tumor IFN–stimulated gene signature termed ISG.RS is associated with a multigenic program of T-cell exhaustion and worse outcomes after immune checkpoint blockade.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“One part of this program is to increase tumor expression of multiple T-cell ligands that lead to exhaustion of T cells infiltrating the TME.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“When tumors express a gene signature (ISG.RS) consisting of genes coordinately activated by multiple types of IFN, a multigenic therapy resistance program is activated.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“Recently, the Minn group elucidated how chronic IFN signaling mediates immunosuppression and resistance to radiation and immune checkpoint inhibitor therapy in solid tumors.2,24,54”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“interferon signaling is of central importance to antitumor immune response43.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Self-citationImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Cited by
Sorted by citations
Items 301–400 of 1,000
An engineered influenza virus to deliver antigens for lung cancer vaccination
Ji, D., Zhang, Y., Sun, J., Zhang, B., Ma, W., Cheng, B., Wang, X., Li, Y., Yu, M., Xu, H., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01796-7 · Cited by 57
A Mechanism of Resistance to Antibody-Targeted Immune Attack
Aldeghaither, D. S., Zahavi, D. J., Murray, J. C., Fertig, E. J., Graham, G. T., Zhang, Y., O’Connell, A., Ma, J., Jablonski, S. A., & Weiner, L. M. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0266 · Cited by 58
Effern, M., Glodde, N., Braun, M., Liebing, J., Boll, H. N., Yong, M. C. R., Bawden, E., Hinze, D., Konijnenberg, D., Daoud, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.007 · Cited by 55
The Tumor Microenvironment of Colorectal Cancer Metastases: Opportunities in Cancer Immunotherapy
Kamal, Y., Schmit, S. L., Frost, H. R., & Amos, C. I. (2020) · Immunotherapy · doi:10.2217/imt-2020-0026 · Cited by 56
van Krimpen, A., Gerretsen, V. I. V., Mulder, E. E. A. P., van Gulijk, M., van den Bosch, T. P. P., von der Thüsen, J. H., Grünhagen, D. J., Verhoef, C. K., Mustafa, D. A. M., Aerts, J. G. J. V., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.009 · Cited by 53
Dou, Y., Chen, R., Liu, S., Lee, Y., Ji, J., Liu, X., Ke, Y., Wang, R., Zhou, Y., & Huang, Y. (2023) · Nature Communications · doi:10.1038/s41467-023-41164-2 · Cited by 58
Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack
Mahmoud, F. A., Shields, B. D., Makhoul, I., Avaritt, N. L., Wong, H. K., Hutchins, L. F., Shalin, S. C., & Tackett, A. J. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1323596 · Cited by 57
Escobar, G., Barbarossa, L., Barbiera, G., Norelli, M., Genua, M., Ranghetti, A., Plati, T., Camisa, B., Brombin, C., Cittaro, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05315-0 · Cited by 54
Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle
Wattenberg, M. M., & Beatty, G. L. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.002 · Cited by 54
Emerging Strategies in TCR-Engineered T Cells
Fang, W., Cheng, X., Xue, J. Z., & Xue, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850358 · Cited by 58
Pu, X., Wu, L., Su, D., Mao, W., & Fang, B. (2018) · BMC Cancer · doi:10.1186/s12885-018-4990-5 · Cited by 56
Vitiello, G. A. F., Ferreira, W. A. S., de Lima, V. C. C., & Medina, T. D. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.782852 · Cited by 59
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors
Zhang, H., Yu, P., Tomar, V. S., Chen, X., Atherton, M. J., Lu, Z. F., Zhang, H.-G., Li, S., Ortiz, A., Gui, J., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00383-0 · Cited by 57
Self-citationShukla, A., Cloutier, M., Santharam, M. A., Ramanathan, S., & Ilangumaran, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041964 · Cited by 55
Precision Medicine in Bladder Cancer: Present Challenges and Future Directions
Mohanty, S. K., Lobo, A., Mishra, S. K., & Liang Cheng, C. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050756 · Cited by 54
Mondal, I., Das, O., Sun, R., Jian, G., Yu, B., Diaz, A. A., Behnan, J., Dubey, A., Meng, Z., Eskandar, E. N., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3382 · Cited by 58
Self-citationAcquired resistance to cancer immunotherapy
Draghi, A., Chamberlain, C. A., Furness, A. J. S., & Donia, M. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0692-y · Cited by 51
Tuccitto, A., Shahaj, E., Vergani, E., Ferro, S., Huber, V., Rodolfo, M., Castelli, C., Rivoltini, L., & Vallacchi, V. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2477-z · Cited by 54
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Michielin, O. A., Lalani, A. A., Robert, C., Sharma, P., & Peters, S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003024 · Cited by 52
Mariniello, A., Borgeaud, M., WEINER, M. H., Frisone, D., Kim, F., & Addeo, A. (2025) · BioDrugs · doi:10.1007/s40259-024-00700-2 · Cited by 61
Xu, X., Xu, J. M., Wu, J., Hu, Y., Han, Y., Gu, Y., Zhao, K., Zhang, Q., Liu, X., Liu, J., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.011 · Cited by 53
Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
Seto, T., Sam, D. L., & Pan, M. (2019) · Medical Sciences · doi:10.3390/medsci7020014 · Cited by 52
Wu, R., Wang, C., Li, Z., Xiao, J., Li, C., Wang, X., Kong, P., Cao, J., Huang, F., Li, Z., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001037 · Cited by 52
Guo, W., Wang, Y., Yang, M., Wang, Z., Wang, Y., Chaurasia, S., Wu, Z., Zhang, M., Yadav, G. S., Rathod, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb3555 · Cited by 50
Zemek, R. M., Chin, W. L., Fear, V. S., Wylie, B., Casey, T. H., Forbes, C., Tilsed, C. M., Boon, L., Guo, B. B., Bosco, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32567-8 · Cited by 51
Zhang, Y., Wang, M., Ye, L., Shen, S., Zhang, Y., Qian, X., Zhang, T., Yuan, M., Ye, Z., Cai, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45712-2 · Cited by 53
Interferons: role in cancer therapy
Abdolvahab, M. H., Darvishi, B., Zarei, M., Majidzadeh-A, K., & Farahmand, L. (2020) · Immunotherapy · doi:10.2217/imt-2019-0217 · Cited by 50
Ioannou, N., Hagner, P. R., Stokes, M., Gandhi, A. K., Apollonio, B., Fanous, M., Papazoglou, D., Sutton, L., Rosenquist, R., Amini, R., et al. (2020) · Blood · doi:10.1182/blood.2020006073 · Cited by 49
Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
Zhou, K., Li, S., Zhao, Y., & Cheng, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127071 · Cited by 49
Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand
Kang, S. W., Lee, S. C., Park, S. H., Kim, J., Kim, H. H., Lee, H., Seo, S. K., Kwon, B. S., Cho, H. R., & Kwon, B. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0610 · Cited by 49
PD-1 /PD-L1 checkpoint in hematological malignancies
Annibali, O., Crescenzi, A., Tomarchio, V., Pagano, A., Bianchi, A., Grifoni, A., & Avvisati, G. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.01.014 · Cited by 49
Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti–PD-1 response in NSCLC
Bullock, B., Kimball, A. K., Poczobutt, J. M., Neuwelt, A. J., Li, H. Y., Johnson, A. M., Kwak, J., Kleczko, E. K., Kaspar, R. E., Wagner, E. K., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201900328 · Cited by 50
Progesterone Receptor Attenuates STAT1-Mediated IFN Signaling in Breast Cancer
Goodman, M. L., Trinca, G. M., Walter, K. R., Papachristou, E. K., D’Santos, C. S., Li, T., Liu, Q., Lai, Z., Chalise, P., Madan, R., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801152 · Cited by 48
Lorenzo, S. D., Tovoli, F., & Trevisani, F. (2022) · Cancers · doi:10.3390/cancers14194616 · Cited by 53
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection
Banna, G. L., Passiglia, F., Colonese, F., Canova, S., Menis, J., Addeo, A., Russo, A. D., & Cortinovis, D. L. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.06.016 · Cited by 48
Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells
Chen, Y., He, X., Lu, Q., Shi, W., Yuan, L., Huang, M., Xu, Y., Chen, X., Gu, L., Zhang, L., et al. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114940 · Cited by 48
Chicas-Sett, R., Zafra, J., Rodríguez‐Abreu, D., Castilla-Martinez, J., Benítez, G., Salas-Salas, B., Hernández, S., Lloret, M., Onieva, J. L., Barragán, I., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.05.013 · Cited by 48
The paradox of radiation and T cells in tumors
Gough, M. J., & Crittenden, M. R. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100808 · Cited by 51
The role of mitochondria in the resistance of melanoma to PD-1 inhibitors
Du, F., Yang, L.-H., Liu, J., Wang, J., Fan, L., Duangmano, S., Liu, H., Liu, M., Wang, J., Zhong, X., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04200-9 · Cited by 47
The role of CD4+ T cells in tumor and chronic viral immune responses
Xie, L., Fang, J., Yu, J., Zhang, W., He, Z., Ye, L., & Wang, H. (2023) · MedComm · doi:10.1002/mco2.390 · Cited by 54
Boumelha, J., de Castro, A., Bah, N. K., Cha, H., Trécesson, S. D. C., Rana, S., Tomaschko, M., Anastasiou, P., Mugarza, E., Moore, C., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2627 · Cited by 51
Chiang, S., Huang, K. C., Ke, T., Chen, T.-W., Lan, Y.-C., You, Y., Chen, W. T., & Chao, K. S. C. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2275-0 · Cited by 49
Dieters‐Castator, D. Z., Rambau, P., Kelemen, L. E., Siegers, G. M., Lajoie, G., Postovit, L.-M. M., & Köbel, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3818 · Cited by 49
Discovery of Small Molecules for the Reversal of T Cell Exhaustion
Marro, B. S., Žák, J., Zavareh, R. B., Teijaro, J. R., Lairson, L. L., & Oldstone, M. B. A. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.119 · Cited by 47
Zhu, C., Chen, X., Guan, G., Zou, C., Guo, Q., Cheng, P., Cheng, W., & Wu, A. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s237162 · Cited by 48
Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma
Zhang, N., Li, W., Ye, M., Kang, C., & You, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.592612 · Cited by 50
Clark, N. M., Martinez, L. M., Murdock, S. J., DeLigio, J. T., Olex, A. L., Effi, C., Dozmorov, M. G., & Bos, P. D. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108482 · Cited by 50
Bai, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.06.001 · Cited by 50
Wang, Y., Drum, D. L., Sun, R., Zhang, Y., Chen, F., Sun, F., Dal, E., Yu, L., Jia, J., Arya, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41282-x · Cited by 51
The Use of the Humanized Mouse Model in Gene Therapy and Immunotherapy for HIV and Cancer
Carrillo, M. A., Zhen, A., & Kitchen, S. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00746 · Cited by 46
Dünker, N., & Jendrossek, V. (2019) · Cancers · doi:10.3390/cancers11101499 · Cited by 56
Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker
Fountzilas, E., Kurzrock, R., Vo, H. H., & Tsimberidou, A. M. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab067 · Cited by 44
Redman, J. M., Tsai, Y.-T., Weinberg, B. A., Donahue, R. N., Gandhy, S. U., Gatti-Mays, M. E., Sater, H. A., Bilušić, M., Cordes, L. M., Steinberg, S. M., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab046 · Cited by 48
EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1
Pan, Y., Shu, G., Fu, L., Huang, K., Zhou, X., Gui, C., Liu, H., Jin, X., Chen, M., Li, P., et al. (2023) · Advanced Science · doi:10.1002/advs.202206792 · Cited by 47
Dervovic, D., Malik, A., Chen, E. L. Y., Narimatsu, M., Adler, N., Afiuni‐Zadeh, S., Krenbek, D., Martinez, S., Tsai, R., Boucher, J. G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38841-7 · Cited by 48
Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Zhang, G., Wu, L. W., Mender, I., Barzily-Rokni, M., Hammond, M. R., Ope, O., Cheng, C., Vasilopoulos, T., Randell, S., Sadek, N. L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2773 · Cited by 44
Self-citationWolf, D. G. F., Fiegl, H., Zeimet, A. G., Wieser, V. E., Marth, C., Sprung, S., Sopper, S., Hartmann, G., Reimer, D., & Boesch, M. (2019) · International Journal of Cancer · doi:10.1002/ijc.32818 · Cited by 45
The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation
Musella, M., Galassi, C., Manduca, N., & Sistigu, A. (2021) · Biology · doi:10.3390/biology10090856 · Cited by 45
Grass, G. D., Alfonso, J. C. L., Welsh, E. A., Ahmed, K. A., Teer, J. K., Pilon‐Thomas, S., Harrison, L. B., Cleveland, J. L., Mulé, J. J., Eschrich, S. A., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.03.006 · Cited by 44
B2M and JAK1/2–mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy
Zhang, C., Li, D., Xiao, B., Zhou, C., Jiang, W., Tang, J., Li, Y., Zhang, R., Han, K., Hou, Z., et al. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000417 · Cited by 44
Chen, L., Zhai, W., Zheng, X. W., Xie, Q., Zhou, Q., Tao, M., Zhu, Y., Wu, C., & Jiang, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000486219 · Cited by 44
Critical role of post-transcriptional regulation for IFN-γ in tumor-infiltrating T cells
Salerno, F., Guislain, A., Heeren, J. J. F., Nicolet, B. P., Young, H. A., & Wolkers, M. C. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1532762 · Cited by 45
Interplay between dendritic cells and cancer cells
Martínek, J., Wu, T.-C., Cadena, D., Banchereau, J., & Palucka, K. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.07.008 · Cited by 45
Self-citationYu, L., Zhu, D., Zhu, L., Hou, Y., Hou, L., Huang, X. Y., Li, L., Wang, Y., Li, L., Zou, H., et al. (2019) · Journal of Cancer · doi:10.7150/jca.34650 · Cited by 44
Self-citationHo, A. Y., Wright, J. L., Blitzblau, R. C., Mutter, R. W., Duda, D. G., Norton, L., Bardia, A., Spring, L. M., Isakoff, S. J., Chen, J. H., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.05.011 · Cited by 45
Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance
Liu, S., İmani, S., Deng, Y., Pathak, J. L., Wen, Q., Chen, Y., & Wu, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s256708 · Cited by 44
Radiation-induced Adaptive Response: New Potential for Cancer Treatment
Coleman, C. N., Eke, I., Makinde, A. Y., Chopra, S., Demaria, S., Formenti, S. C., Martello, S. E., Bylicky, M. A., Mitchell, J. B., & Aryankalayil, M. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0572 · Cited by 46
Glioma escape signature and clonal development under immune pressure
Maire, C. L., Mohme, M., Bockmayr, M. L., Fita, K. D., Riecken, K., Börnigen, D., Alawi, M., Failla, A. V., Kolbe, K., Zapf, S., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138760 · Cited by 44
Marín‐Jiménez, J. A., Capasso, A., Lewis, M. S., Bagby, S. M., Hartman, S. J., Shulman, J., Navarro, N. M., Yu, H., Rivard, C. J., Wang, X., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.607282 · Cited by 45
IFNγ Signaling in Natural and Therapy-Induced Antitumor Responses
Martínez, A., Arenas, E. J., & Arribas, J. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3226 · Cited by 47
Stein, R. G., Ebert, S., Schlahsa, L., Scholz, C. J., Braun, M., Hauck, P., Horn, E., Monoranu, C., Thiemann, V., Wustrow, M. P., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0387 · Cited by 44
Inflammatory signaling in genomically instable cancers
Talens, F., & van Vugt, M. A. T. M. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1638192 · Cited by 43
Rouanne, M., Adam, J., Radulescu, C., Letourneur, D., Bredel, D., Mouraud, S., Goubet, A.-G., Leduc, M., Chen, N., Tan, T. Z., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci145666 · Cited by 44
Emerging Biomaterials Imaging Antitumor Immune Response
Ma, X., Zhang, M., Wang, J., Zhang, T., Xue, P., Kang, Y., Sun, Z., & Xu, Z. (2022) · Advanced Materials · doi:10.1002/adma.202204034 · Cited by 42
Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer
Jenkins, R. W., Thummalapalli, R., Carter, J., Cañadas, I., & Barbie, D. A. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-060116-022926 · Cited by 42
Tang, W., Wallace, T. A., Yi, M., Magi‐Galluzzi, C., Dorsey, T. H., Onabajo, O. O., Obajemu, A. A., Jordan, S. V., Loffredo, C. A., Stephens, R. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1060 · Cited by 43
Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
Olbryt, M., Rajczykowski, M., & Widłak, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114071 · Cited by 42
Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment
Chen, C., Liu, Y., & Cui, B. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1840254 · Cited by 43
Penter, L., Zhang, Y., Savell, A., Huang, T., Cieri, N., Thrash, E. M., Kim‐Schulze, S., Jhaveri, A., Fu, J., Ranasinghe, S., et al. (2021) · Blood · doi:10.1182/blood.2021010867 · Cited by 45
Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy
Marcus, D., Lieverse, R. I. Y., Klein, C., Abdollahi, A., Lambin, P., Dubois, L. J., & Yaromina, A. (2021) · Cancers · doi:10.3390/cancers13061468 · Cited by 43
Song, J., Yang, R., Wei, R., Du, Y., He, P., & Liu, X. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00475-8 · Cited by 43
Giricz, O., Mo, Y., Dahlman, K. B., Cotto-Rios, X. M., Vardabasso, C., Nguyen, H., Matusow, B., Bartenstein, M., Polishchuk, V., Johnson, D. B., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120422 · Cited by 40
Franzese, O., & Graziani, G. (2022) · Cancers · doi:10.3390/cancers14225633 · Cited by 44
Targeting STING Activation by Antigen‐Inspired MnO2 Nanovaccines Optimizes Tumor Radiotherapy
Gu, Y., Lin, S., Wu, Y., Xu, P., Zhu, W., Wang, Y., Cheng, X., Zhang, L. W., Stauber, R. H., Wang, Y., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300028 · Cited by 41
Panagi, M., Mpekris, F., Voutouri, C., Hadjigeorgiou, A. G., Symeonidou, C., Porfyriou, E., Michael, C., Stylianou, A., Martin, J. D., Cabral, H., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0246 · Cited by 47
Au-Yeung, N., & Horvath, C. M. (2018) · iScience · doi:10.1016/j.isci.2018.07.013 · Cited by 44
McCaw, T. R., Li, M., Starenki, D., Cooper, S. J., Liu, M., Meza‐Perez, S., Arend, R. C., Buchsbaum, D. J., Forero, A., & Randall, T. D. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2262-5 · Cited by 41
Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy
Hirukawa, A., Singh, S., Wang, J. H., Rennhack, J. P., Swiatnicki, M., Sanguin‐Gendreau, V., Zuo, D., Daldoul, K., Lavoie, C. A., Park, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.105 · Cited by 43
CRISPR screen in mechanism and target discovery for cancer immunotherapy
Liu, D., Zhao, X., Tang, A., Xu, X., Liu, S., Zha, L., Ma, W., Zheng, J., & Shi, M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188378 · Cited by 44
Segura‐Bayona, S., Villamor-Payà, M., Attolini, C. S., König, L. M., Sanchiz-Calvo, M., Boulton, S. J., & Stracker, T. H. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107983 · Cited by 43
Self RNA Sensing by RIG-I–like Receptors in Viral Infection and Sterile Inflammation
Stok, J. E., Quiroz, M. E. V., & van der Veen, A. G. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000488 · Cited by 41
Breast cancer resistance mechanisms: challenges to immunotherapy
Hanna, A., & Balko, J. M. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06337-x · Cited by 45
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma
Santoni, M., Mollica, V., Rizzo, A., & Massari, F. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102881 · Cited by 43
Wu, Y., Yan, Y., Guo, Y., Niu, M., Zhou, B., Zhang, J., Zhou, P., Chu, Q., Mei, Q., Yi, M., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01678-2 · Cited by 43
Hyperprogression: A novel response pattern under immunotherapy
Han, X., Alu, A., Xiao, Y., Wei, Y., & Wei, X. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.167 · Cited by 41
Impact of cancer evolution on immune surveillance and checkpoint inhibitor response
Wu, Y., Biswas, D., & Swanton, C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.013 · Cited by 43
Networks of CD8+ T Cell Response Activation in Melanoma and Vitiligo
Fukuda, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.866703 · Cited by 42
Turan, T., Kongpachith, S., Halliwill, K. D., Roelands, J. P., Hendrickx, W., Marincola, F. M., Hudson, T. J., Jacob, H. J., Bedognetti, D., Samayoa, J. A., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01145-4 · Cited by 40
Han, S., Wang, P., Cai, H., Wan, J., Li, S., Lin, Z.-H., Yu, C., & Yan, C. (2021) · Aging · doi:10.18632/aging.203102 · Cited by 38
Wong, C. W., Evangelou, C., Sefton, K. N., Leshem, R., Zhang, W., Gopalan, V., Chattrakarn, S., Carro, M. L. F., Uzuner, E., Mole, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41737-1 · Cited by 42
Metadata
- Authors
- Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., Gangadhar, T. C., Amaravadi, R. K., Schuchter, L. M., Feldman, M. D., Ishwaran, H., Vonderheide, R. H., Maity, A., Wherry, E. J., & Minn, A. J.
- Affiliations
- University of Pennsylvania (US)
- University of Miami (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Minn, Andy J.
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 167
- Issue
- 6
- Pages
- 1540-1554.e12
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC5385895
- OpenAlex
- W2558219863
- Cited by
- 1,216
- References
- 42
- Citations by year
- 2026: 150 · 2025: 124 · 2024: 127 · 2023: 135 · 2022: 128 · 2021: 140 · 2020: 140 · 2019: 114 · 2018: 92 · 2017: 64 · 2016: 1
- FWCI
- 48.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Apollo
- Funders
- Melanoma Research Alliance
- Parker Institute for Cancer Immunotherapy
- Robertson Foundation
- Cancer Research Institute Irvington Fellowship
- NIH (P50CA174523, R01CA163739, R01CA158186, P30CA016520, U19AI082630, R01AI105343, U01AI095608, P01AI112521)
- Basser Research Center for BRCA
- Abramson Cancer Center Translational Center of Excellence in Pancreatic Cancer
- Department of Defense Era of Hope Scholar (W81XWH-09-1-0339)
- NCI (R01CA172651)
- Merck
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune checkpoint inhibitor resistance, type I interferon, interferon-gamma, PD-1 pathway, PD-L1, STAT1, interferon-stimulated genes, T cell inhibitory receptors, T cell exhaustion, radiotherapy, tumor immune microenvironment, resistance biomarkers, anti-PD-1 therapy
- MeSH terms
- Animals, Humans, Interferons, Melanoma, Neoplasm Transplantation, T-Lymphocytes, Radioimmunotherapy, Drug Resistance, Neoplasm, Cell Line, Tumor, STAT1 Transcription Factor, Mice, B7-H1 Antigen, CTLA-4 Antigen, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
